| Efficacy and tolerance of recombinant tissue-type plasminogen activator in patients with thrombotic or embolic occlusions of leg-arteries. | |
| | |
MedLine Citation:
|
PMID: 8471820 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The efficacy and safety of recombinant tissue-type plasminogen activator (rt-PA) was evaluated in 46 patients with thromboembolic arterial occlusions in leg arteries. rt-PA was given over 1-4 h with a maximum dose of 18 mg. The effect of rt-PA treatment was determined as patency of the occluded arteries in 44 different patients 14 days after treatment. In 41 patients at least one artery was recanalized (93%) by rt-PA, and in almost half of these patients (48%) no residual stenosis were detected after the lytic treatment. A slight residual stenosis was detected in 29% of the patients and a severe residual stenosis in 21%. An additional treatment with percutaneous transluminal angioplasty was performed in 23 of the 44 patients and successful in 21 (91%). In 8 patients an addition catheter-embolectomy was performed. No difference in patency rate was detected between patients with thrombotic and those with embolic occlusions. The age of the occlusion influenced the patency rate; occlusions under the age of 5 weeks showed a patency rate of 96% compared to 82% in older occlusions. The length of the occlusion did not have any influence on the outcome of the rt-PA treatment. From the results of this open study we conclude that a dose of up to 18 mg of rt-PA is both safe and effective in the treatment of thromboembolic occlusions in leg arteries. |
| | |
Authors:
|
F A Spengel; G Küffer; H Stiegler |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: The Clinical investigator Volume: 71 ISSN: 0941-0198 ISO Abbreviation: Clin Investig Publication Date: 1993 Apr |
Date Detail:
|
Created Date: 1993-05-18 Completed Date: 1993-05-18 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 9207154 Medline TA: Clin Investig Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 323-6 Citation Subset: IM |
Affiliation:
|
Medizinische Poliklinik, Universität München. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Arterial Occlusive Diseases / drug therapy* Female Humans Leg / blood supply* Male Middle Aged Popliteal Artery Recombinant Proteins / therapeutic use Thromboembolism / drug therapy* Thrombolytic Therapy / methods* Tissue Plasminogen Activator / therapeutic use* Treatment Outcome Vascular Patency |
| Chemical | |
Reg. No./Substance:
|
0/Recombinant Proteins; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chronic pentamidine aerosol prophylaxis does not induce QT prolongation.
Next Document: Selective intra-lysosomal concentration of niobium in kidney and bone marrow cells: a microanalytica...